NCT02697240View on ClinicalTrials.gov

A Phase 1 Study of Continuous Intravenous L-citrulline During Sickle Cell Pain Crisis or Acute Chest Syndrome

PHASE1CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

April 30, 2017

Study Completion Date

April 30, 2017

Conditions
Sickle Cell Disease
Interventions
DRUG

Intravenous citrulline

Intravenous citrulline at a bolus dose of 20 mg/kg over 5 minutes and then continuous at a rate of 7 mg/kg/hour for the next 23 hours for the first 7 participants, and depending on safety and pharmacokinetic profile, increase or decrease the continuous rate to 9 or 5 mg/kg/hour for the next 7 participants.

Trial Locations (1)

39216

University of Mississippi Medical Center, Jackson

All Listed Sponsors
lead

University of Mississippi Medical Center

OTHER

NCT02697240 - A Phase 1 Study of Continuous Intravenous L-citrulline During Sickle Cell Pain Crisis or Acute Chest Syndrome | Biotech Hunter | Biotech Hunter